Trial · NCT01882816

Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer

NCT01882816, Phase 2, Completed, Memorial Sloan Kettering Cancer Center; results first posted 2022-12-29

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer. Trials, record NCT01882816. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01882816

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer
NCT number: NCT01882816
Status: Completed
Phases: Phase 2
Enrollment: 27 participants, actual
Lead sponsor: Memorial Sloan Kettering Cancer Center
Conditions: Thyroid Cancer
Interventions: IMRT, DWI MRI, Doxorubicin, Modified Barium Swallow Impairment Profile (MBSImP)
First posted: 2013-06-20
Last updated: 2022-12-29
Results first posted: 2022-12-29

Source ClinicalTrials.gov

Registered outcomes6

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Percentage of Participants With Local-regional Progression-free Survival	2 years	2-year cumulative incidence of locoregional progression/failure with death as a competing risk will be defined as infield progression if included in the RT field and meets one of the following criteria: 25% increase in tumor volume, new lesions, and/or 25% increase in metabolic tumor volume or total lesion glycolysis.
Secondary	Overall Survival	2 years
Secondary	Percentage of Participants With Grade 3 or Higher Treatment-related Toxicities	2 years	During radiation, adverse events will be graded using the NCI Common Terminology Criteria for Adverse Events-Version 4.0 Physician-reported acute grade 3 or higher treatment-related toxicities, regardless of attribution.
Secondary	Rate of Late Dysphagia	2 years	Grade 2 or higher late toxicity rate. During radiation, adverse events will be graded using the NCI Common Terminology Criteria for Adverse Events-Version 4.0
Secondary	Rate of Late Xerostomia/Dry Mouth	2 years	Rate of late xerostomia/dry mouth. During radiation, adverse events will be graded using the NCI Common Terminology Criteria for Adverse Events-Version 4.0
Secondary	Number of Participants With Significant Functional Difference in Dysphagia at 12 Months Compared to Baseline	12 months	Comparison of significant functional differences 12 months after treatment assessed using standard Modified Barium Swallow Study

Source ClinicalTrials.gov

Outcomes6

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Percentage of Participants With Local-regional Progression-free Survival	2 years	percentage of all participants	NUMBER
SECONDARY	Overall Survival	2 years	percentage of participants alive	NUMBER
SECONDARY	Percentage of Participants With Grade 3 or Higher Treatment-related Toxicities	2 years	percentage of participants	NUMBER
SECONDARY	Rate of Late Dysphagia	2 years	percent of pts experiencing dysphagia	NUMBER
SECONDARY	Rate of Late Xerostomia/Dry Mouth	2 years	percent of pts experiencing dry mouth	NUMBER
SECONDARY	Number of Participants With Significant Functional Difference in Dysphagia at 12 Months Compared to Baseline	12 months	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group7

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Percentage of Participants With Local-regional Progression-free Survival	IMRT and Doxorubicin		15.2		percentage of all participants
Overall Survival	IMRT and Doxorubicin		77.3	95% Confidence Interval 62.8 to 95.1	percentage of participants alive
Percentage of Participants With Grade 3 or Higher Treatment-related Toxicities	IMRT and Doxorubicin		33.4		percentage of participants
Rate of Late Dysphagia	IMRT and Doxorubicin		8.0		percent of pts experiencing dysphagia
Rate of Late Xerostomia/Dry Mouth	IMRT and Doxorubicin		4.0		percent of pts experiencing dry mouth
Number of Participants With Significant Functional Difference in Dysphagia at 12 Months Compared to Baseline	IMRT and Doxorubicin	Participants with significant functional difference as compared to baseline	0		Participants
Number of Participants With Significant Functional Difference in Dysphagia at 12 Months Compared to Baseline	IMRT and Doxorubicin	Participants without significant functional difference as compared to baseline	27		Participants

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	IMRT and Doxorubicin	27
Overall Study	COMPLETED	IMRT and Doxorubicin	27
Overall Study	NOT COMPLETED	IMRT and Doxorubicin	0

Source ClinicalTrials.gov

Adverse events9

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Anemia	Blood and lymphatic system disorders	IMRT and Doxorubicin	4	27
other	Hyperglycemia	Metabolism and nutrition disorders	IMRT and Doxorubicin	4	27
other	Hypocalcemia	Metabolism and nutrition disorders	IMRT and Doxorubicin	3	27
other	Lymphocyte count decreased	Investigations	IMRT and Doxorubicin	22	27
other	Neutrophil count decreased	Investigations	IMRT and Doxorubicin	4	27
other	Platelet count decreased	Investigations	IMRT and Doxorubicin	3	27
other	White blood cell decreased	Investigations	IMRT and Doxorubicin	4	27
serious	Stoma site infection	Infections and infestations	IMRT and Doxorubicin	1	27
serious	Stridor	Respiratory, thoracic and mediastinal disorders	IMRT and Doxorubicin	3	27

Source ClinicalTrials.gov

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	IMRT and Doxorubicin	11	27
Total, other adverse events	IMRT and Doxorubicin	22	27
Total, serious adverse events	IMRT and Doxorubicin	3	27

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
34293201	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01882816

GET https://conductscience.org/api/trials/v1/NCT01882816/registered

API reference For AI assistants